Advent Gains High-Potential ART Business Through Bharat Buy
Deal Gives Exit To Other PE Groups
With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.
You may also be interested in...
How Ex-Janssen India Chief Is Steering Bharat Serums’ Ambitions In Women’s Health
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
Bharat Serums Takes Shot At Ulinastatin For COVID-19 Respiratory Distress
Private equity-controlled Bharat Serums and Vaccines gets go-ahead in India for COVID-19-related trials with ulinastatin, an existing sepsis therapy for which it is the leading player in the country. Management also outlines how the firm is ensuring business continuity during this challenging phase.
A Decade’s Deals In Indian Pharma Point To 2020 Trends
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.